Volume. 1, July - September, 2012 - amam-ayurveda.org

Table 1: Pattern of Improvement in the subjects with increased duration
of cycles
Duration Baseline Cycle
1
(>32 days)
Increased
cycles
Mean 46.15
(n=26)
35.03
(n=26)
Cycle 2 Cycle
3
35.65
(n=26)
30.45
(n=22)
± 18.9 ± 9.72 ± 7.82 ± 4.04
Mean
Change
Info Ayurveda, Volume 2, No.1, July to September’ 2012
%
reduction
15.7 34.01
4.1.2. Effect of WHS on decreased duration of cycles (n=5):
In subjects reporting with decreased duration of cycles (n=5), mean
duration was 17.80 (+ 03.97) days at baseline. After intervention
with the trial drug, all the subjects (100%) have achieved near normal
duration of cycles by the end of fourth cycle with a mean duration of
23.60 (+ 07.16) days. Mean change was 05.80 days i.e., 32.58% increase
in duration of cycle with P32 days)
Increased
cycles
Mean 17.80
(n=5)
22.60
(n=5)
Cycle
2
23.00
(n=5)
Cycle
3
22.20
(n=5)
Cycle
4
23.60
(n=5)
SD ±3.97 ±3.43 ±2.73 ±4.49 ±7.16
4.2. Effect of trial drug on irregular bleeding days
Mean
Change
%
reduction
5.8 32.58
4.2.1. Effect on increased bleeding days (n=11):
After the intervention with the trial drug none of the subjects shown
normal bleeding days by the 3rd cycle. Only 4 subjects (36.67%) have
shown normal bleeding days pattern during the 4th cycle. The mean
number of days of improvement was 0.97 days i.e., a percentage reduction
of 14.43% with P>0.05
Table 3: Effect of trial drug in subjects with increased bleeding days
Duration Baseline Cycle
1
(>32 days)
Increased
cycles
Mean 03.75
(n=8)
04.25
(n=8)
Cycle
2
04.25
(n=8)
Cycle
3
04.13
(n=8)
Cycle
4
04.20
(n=5)
SD ± 0.7 ± 1.4 ± 1.3 ± 0.9 ± 0.8
Mean
Change
%
reduction
0.45 12.00%
4.2.2. Effect on decreased bleeding days (n=8):
After the intervention with the trial drug all the subjects have shown
normal bleeding days by the 3rd cycle (4.2 days + 0.90). The mean number
of increase in bleeding days was 0.45 days i.e., a percentage increase of
12.00% with P>0.05.
Table 4: Effect of trial drug in subjects with decreased bleeding days
Duration Baseline Cycle 1 Cycle
2
( > 3 2
days)
Increased
cycles
Mean 17.80
(n=5)
22.60
(n=5)
23.00
(n=5)
Cycle
3
22.20
(n=5)
Cycle
4
23.60
(n=5)
SD ±3.97 ±3.43 ±2.73 ±4.49 ±7.16
Mean
Change
%
reduction
5.8 32.58
4.2.3. Effect of Trial drug on number of pads (increased duration of
cycles): (n=26)
The reduction in number of pads in case of subjects having increased
duration of cycles was 21.4 at baseline against 19.4 at the end of 4th
cycle.
Table 5: Efficacy of WHS on no. of pads in increased duration of cycles
Baseline
(n=26)
cycle 1
(n=26)
Cycle 2
(n=26)
Cycle 3
(n=22)
No. of pads 21.4 24.42 26.5 23.4 19.4
Cycle 4 (n=5)
4.2.4. Effect of trial drug on number of pads (decreased duration of
cycle): (n=5)
There was an increase in number of pads in case of subjects having
decreased duration of cycles viz., 16.3 at baseline against 21.4 at the end
of 4th cycle.
Table 6: Efficacy of WHS on no. of pads in decreased duration of cycles
No. of
pads
Baseline
(n=5)
cycle 1
(n=5)
Cycle 2
(n=5)
Cycle 3
(n=5)
Cycle
4
(n=5)
Cycle 5
(n=5)
16.3 21.1 19.8 23.1 21.4 28.75
4.2.5. Effect of trial drug on menstrual flow (increased duration of
Cycle): (n=26)
Among 26 subjects in the increased duration of cycle, there were 9 with
heavy flow and 8 with scanty flow. Remaining 9 subjects presented with
moderate (normal) flow. In the heavy flow category only one subject was
left with heavy bleeding by 3rd cycle. Among the scanty flow category 2
were left with scanty flow by 3rd cycle.
Table 7: Efficacy of WHS on amount of flow in increased duration of
cycles
Flow Baseline cycle 1 Cycle 2 Cycle 3 Cycle 4
Heavy 9 7 2 2
Moderate 9 14 19 19 5
Scanty 8 5 5 2
4.2.6. Effect of trial drug on menstrual flow (decreased duration of
Cycle): (n=5)
In case of decreased duration of cycles, 2 had heavy flow and 3 had
moderate (normal) flow. By 4th cycle all the subjects have fallen under
the moderate flow category.
Table 8: Efficacy of WHS on amount of flow in decreased duration of
cycles
Flow Baseline cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5
Heavy 2 1 1 1 0 0
Moderate 3 4 4 4 5 2
Scanty 0 0 0 0 0 0
13